PELOBIOTECH to Distribute Noviocell's Products

Agreement gives PELOBIOTECH distribution rights to full synthetic hydrogel 3D Culture product line

Pic: Hydrogel (Noviocell) (PresseBox) ( Planegg/Martinsried, )
PELOBiotech GmbH announces the partnership with the highly innovative biotech company Noviocell BV (Oss, Netherlands). From September 2018 on the 3D cell culture specialist PELOBiotech gets the distribution rights to Noviocell’s full product line for the life science research market within DACH.

Noviocell BV has established a smart synthetic hydrogel for 3D Cell Culture ranging from organoid growth to personalized medicine. These hydrogels can easily change their physical condition enabling easy-to-use 3D cell culture products.

Noviogel is a bioelastic reversible thermosensitive synthetic solution for 3D Culture based on Polyisocyanopeptide (PIC) hydrogel, a new class of advanced polymers. PIC hydrogel is an improved platform for cell studies, because it combines the unique benefits of natural and synthetic biomaterials. PIC hydrogels uniquely perform like collagen, while possessing the same characteristics as other commercial hydrogels. Furthermore, it is fully reversible thermo sensitive, cells can be easy recovered and downstream processing after culturing is straightforward.

Noviocell Syntrix is a synthetic, bioactive cell culture matrix based on self-assembling hydrogel technology. Gels form rapidly and spontaneously under physiological conditions from appropriate precursor solutions, allowing mild encapsulation of cells.

“It’s a novel ground breaking technology that radically improves stem cell research and revolutionizes the field of 3D cell culture.”, said Dr. Juliette van den Dolder, CEO of Noviocell. “I`m sure this great technology improves personalized drug screening radically and will reform the current therapeutic options for regenerative medicine”, said Dr. Peter Frost, PELOBiotech’s CEO and leading 3D Cell Culture expert.

“Noviocell is very happy to have PELOBiotech representing our products”, said Dr. Juliette van den Dolder, CEO at Noviocell. “We have got to know Peter Frost, one of the founders of PELOBiotech, as one of the big players in the 3D market. Having Peter and PELOBiotech representing our products is a big step for us and a great fit.”

Said Dr. Peter Frost, CEO of PELOBiotech: “We are delighted to now be distributing Noviocell. The tremendous progress of these products will reflect a great advantage to the academic landscape and pharma companies. Those often have a strong need for reproducibility and no batch-to batch variation. Synthetic hydrogels fit very well with PELOBiotech’s goal to provide consistent and easy-to-use solutions to support our customers’ research.”

About Noviocell BV
Noviocell BV is a highly innovative biotech company headquartered in Oss, The Netherlands. It focuses on the development of the first ever synthetic solution for 3D cell culturing, ranging from organoid growth to personalized medicine.Noviocell develops easy-to-use solutions for biomedical researchers, biotech and pharma industry and clinicians building upon its two proprietary hydrogel technologies: the soft thermo-responsive helical oligo(ethylene)glycol polyisocyanopeptides (PICs) hydrogel and the programmed self-assembly of peptide-modified cyclohexane triacid derivatives into self-assembled nanofibers.

For more information, please contact:

Dr. Peter Frost | CEO
Christiane Büchsel | Corporate Communications & Marketing
Tel: +49 (0) 89 / 517 286 59 0

Noviocell BV
Dr. Juliette van den Dolder | CEO
T +31 6 461 550 64

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an